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  Chronic anterior knee pain (AKP) is a disabling 
painful condition associated with signiﬁ  cant 
activity limitation and reduced quality of life.  1   It 
has a multifactorial aetiology with biomechanical 
abnormalities, anatomical variations and under-
lying pathology all potentially contributing.  2     3   
Conservative therapy may improve outcomes 
for some individuals with AKP  4    –    6  ; however, as 
many as one in four patients experience chronic 
knee symptoms.  7   Abnormal lateral tracking of the 
patella, associated with an imbalance in activation 
of the medial and lateral components of the quad-
riceps muscle, has been proposed as a possible con-
tributor to AKP.  8   Consequently, it is possible that 
treatment using botulinum toxin type A (BoNT-A) 
to address the imbalance between the relatively 
o v e r a c t i v e  v a s t u s  l a t e r a l i s  ( V L )  m u s c l e  a n d  t h e  
less active vastus medialis (VM) may alleviate 
symptoms.  9   Intramuscular injection of BoNT-A 
produces temporary presynaptic blockade of ace-
tylcholine release, resulting in a dose-dependent 
weakening of muscle contraction. In animal mod-
els, restoration of muscle function has been shown 
to occur within 3 months of injection; initially due 
to the release of acetylcholine from newly formed 
nerve sprouts and eventually to complete recovery 
of the original nerve ending.  10   
  The aim of this double blind, randomised, pla-
cebo injection controlled crossover trial was to 
investigate the efﬁ  cacy of an intramuscular injec-
tion of BoNT-A to the distal portion of the VL 
muscle to provide a ‘window of opportunity’ to 
re-train the medial quadriceps and thus restore 
more balanced knee extensor control during func-
tional activity. The primary outcomes were knee-
related disability and activity-induced pain at 
12 weeks postinjection. 
  MATERIALS  AND  METHODS 
  The enrolment schedule is shown in   ﬁ  gure 1  .   
  All participants provided written informed con-
sent before enrolment. The study was approved by 
the institutional ethics committee and listed in the 
Australian New Zealand Clinical Trials registry 
(www.anzctr.org.au) ACTRN12605000775617. 
    Subjects and study design 
  Volunteers who were 15–55 years of age, with a 
history of symptoms suggestive of AKP of more 
than 6 months’ duration, who had failed conser-
v a ti v e  c a r e  b u t  h a d  n o  p r e vi o u s  s u r g i c al  in t e r -
v e n t i o n ,  w e r e  s c r e e n e d  b y  p h o n e .  I n d i v i d u a l s  
who met the initial criteria attended for clinical 
assessment to determine eligibility. Consenting 
individuals underwent a screening computed 
tomography examination to exclude those with 
established patellofemoral joint degenerative 
change. Subjects were only included if there was 
clear evidence of VL muscle dominance  11   assessed 
using surface electromyography (EMG) during 
isometric extension in 30° of knee ﬂ  exion. In indi-
viduals without knee pain, the ratio of VL:VM 
activation has been shown to be close to 1:1 dur-
ing an isometric contraction at 10° knee ﬂ  exion.  12   
Individuals were excluded if they had excessive 
patellofemoral joint laxity or previous patellar 
dislocation, body mass index greater than 30, 
radiographically determined joint degeneration, 
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 ABSTRACT 
  O b j e c t i v e s      This randomised controlled crossover 
trial examined the efﬁ  cacy of botulinum toxin type A 
(BoNT-A) injection, plus an exercise programme, to 
remediate chronic anterior knee pain (AKP) associated 
with quadriceps muscle imbalance.   
  Methods     24 individuals with refractory AKP received 
either BoNT-A (500 U Dysport) or the same volume 
saline injection to the vastus lateralis (VL) muscle and 
performed home exercises focusing on re-training the 
vastus medialis (VM) muscle. All subjects were offered 
open-label injection at 12 weeks. Knee-related disability 
(anterior knee pain scale; AKPS) and activity-induced 
pain (10 cm visual analogue scale) at 12 weeks were the 
primary outcomes. Peak isometric extensor force was 
recorded and normalised VL:VM ratios were derived 
from simultaneous surface electromyography. Self-
reported pain and disability measures were collected at 
six time points to a mean of 20±8 months.   
  Results     14 subjects received BoNT-A and 10 placebo 
injection. Improvement at 12 weeks was signiﬁ  cantly 
greater for BoNT-A compared with placebo-injected 
subjects for the AKPS (p<0.03), pain on kneeling 
(p<0.004), squatting (p<0.02) and level walking 
(p<0.04). At week 12, ﬁ  ve placebo subjects crossed 
over to open-label injection. At 24 weeks, 16 of 19 
BoNT-A-injected and two of the remaining ﬁ  ve placebo-
injected subjects were either satisﬁ  ed or very satis-
ﬁ  ed with treatment outcomes. Improvements were 
maintained in 11 of 14 BoNT-A-injected and two of ﬁ  ve 
placebo subjects available at longer-term follow-up.   
  C o n c l u s i o n      BoNT-A injection produced a greater 
reduction in pain and disability than placebo injection in 
carefully selected patients with chronic AKP related to 
quadriceps muscle imbalance.   
                  Tr e a t m e n t   o f   r e f r a c t o r y   a n t e r i o r   k n e e   p a i n   u s i n g  
botulinum toxin type A (Dysport) injection to the 
distal vastus lateralis muscle: a randomised placebo 
controlled crossover trial   
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or contraindications to BoNT-A injection including pregnancy. 
Subsequently, three baseline assessments were performed, 
at least 1 week apart, to establish the stability of self-report 
and objective measures. Following this a computer-generated 
random assignment was used to allocate subjects in blocks 
of four to BoNT -A or same volume placebo injection. Both 
groups undertook a daily home programme of exercises typi-
cally used in this cohort. Subjects, investigators and assessors 
were blinded to group allocation. At 12 weeks postinjection, 
all subjects had the opportunity to have an open-label BoNT-A 
injection if they considered that there was no change in their 
knee symptoms. Data were not unmasked at this time point. 
Subjects receiving a second injection continued with the exer-
cise programme for a further 12 weeks. Assessments occurred 
at 2, 6, 12, 18 and 24 weeks from each injection. Additional 
self-report data were collected by mailed questionnaires up to 
a mean of 20±8 months after entry to the study.   
  P r o c e d u r e s  
  An intramuscular injection of 500 U Dysport (Ipsen) diluted 
with 4 ml physiological saline was performed by an experi-
enced neurologist (PLS). Needle EMG was used to guide the 
intramuscular injection particularly in the most distal mus-
culotendinous portion of the VL muscle (  ﬁ  gure 2  ). The dose 
was divided and administered over eight injection sites; with 
0.5 ml injected at each site. (  ﬁ  gure 2  ). Placebo subjects received 
the same number of injections and volume of saline. Records 
of group allocation were maintained by a neurophysiology 
technician whose only responsibility was randomisation and 
drawing up the injectate.   
  Subjects were instructed by experienced physiotherapists 
(KPS, BJS) in a standard AKP exercise programme to be per-
f o rm e d  a t  h o m e  twi c e  d ail y .  R e p e ti ti o ns  w e r e  c u s t o mi s e d  
according to the number the individual could perform cor-
rectly without fatigue within a session. Participants kept a 
diary during the 12-week programme to record the number 
of exercises performed and any symptoms experienced. The 
diary was checked and progressions conﬁ  rmed at each clinic 
visit.   
  Outcome  measures 
  The primary outcome was the change in self-reported knee 
pain and disability from baseline to 12 weeks postinjection. 
The third baseline measure was used for all comparisons.   
    The anterior knee pain scale (AKPS)  1.  13   is a 13-item self-
report questionnaire. The maximum score is 100. Lower 
scores indicate greater pain/disability. A change of 14 points 
has previously been reported to be the minimal clinically 
important difference for the AKPS.  14     
    Rating of pain from four potentially pain-provoking activ- 2. 
ities—ascending or descending stairs, kneeling, squatting 
and level walking—was recorded using a 10 cm visual ana-
logue scale (VAS).  15   A change of 20/100 was considered to 
be clinically signiﬁ  cant.  16     
    An overall rating of improvement survey (level of satisfac- 3. 
tion with treatment outcome) was completed at 24 weeks 
postinjection. This questionnaire allowed participants to 
nominate the treatment(s) they thought they had received 
and whether they would have this treatment again. They 
were asked to rate, on a ﬁ  ve-point Likert scale, their current 
status with regard to knee symptoms (swelling, stiffness, 
etc) and pain, restriction in participation in daily living, rec-
reational and work activities (marked worsening to marked 
improvement), in addition to their satisfaction with treat-
ment outcomes (very dissatisﬁ  ed to highly satisﬁ  ed).     
  Two additional variables were examined:   
    Peak knee extensor force during an isometric quadri- 1. 
ceps contraction with the limb ﬁ  xed in 30° of ﬂ  exion was 
assessed using an instrumented dynamometer. Following a 
warm-up, three trials were conducted and the best trial was 
used for analysis. For consistency, a standard instruction 
was given without encouragement during the tests.   
    Normalised VL:VM ratios were derived from surface EMG  2. 
recording using the method reported by Ng and Cheng.  11   
EMG electrode pairs (3M Red-Dot; St Paul, Minnesota, 
USA)   were applied in line with the muscle ﬁ  bre  direc-
tion of VM and VL, using an interelectrode distance of 
25 mm. Raw data for force and surface EMG were sam-
pled at 1000 Hz and stored to disc. EMG recordings used 
a 6–400 Hz bandwidth acquired under Labview software 
(National Instruments Corporation, Austin, Texas, USA). 
A 1000 ms epoch, at the point of peak force, was used to 
extract the EMG signals, which were full-wave rectiﬁ  ed 
and root mean square processed. Force and ratio data at 
baseline were compared with each time point to 12 weeks 
postinjection.     
  Qualitative data were collected from the subjects’ diaries 
to describe any adverse effects, compliance with the home 
  Figure  2         Intramuscular injection of botulinum toxin type A or same 
volume placebo was performed by an experienced injector employing 
electromyography guidance. Multiple injection sites were employed 
to ensure the spread of injectate. A model is depicted for illustrative 
purposes.    
  Figure  1         Study design and subject enrolment. BoNT-A, botulinum 
toxin  type  A.    
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programme, as well as any change in physical activity levels 
during the course of the study.   
  Statistical  analysis 
  An intention to treat analysis was performed. The groups were 
examined for comparability of demographics and self-reported 
pain and disability data at baseline using independent t tests  .   
Repeated measures analysis of variance (StatView) was used 
for planned comparisons (Scheffe) to assess the within-group 
change over time for knee force and EMG ratios; whereas 
unpaired t tests of the change scores were used for between- 
group comparisons. A probability of p<0.05 was adopted for 
all statistical tests.     
  R E S U L T S  
  Study enrolment is summarised in   ﬁ  gure 1  . Twenty-four indi-
viduals met the entry criteria. Subjects had an average dura-
tion of symptoms of 5.7 years (range 1–10). Many had sought 
a surgical opinion and ﬁ  ve cases were wait-listed for surgical 
management. 
  In phase I, 14 individuals received Dysport (eight women, 
six men; mean age 31.5 years (range 15–48), duration of symp-
toms 66 months) and 10 received placebo injection (nine 
women, one man; mean age 27.4 years (range 18–44), duration 
of symptoms 80 months). One placebo subject dropped out of 
the study at 8 weeks due to work-related relocation and was 
lost to follow-up. 
  There were no statistically signiﬁ  cant differences between 
the groups in any of the measured variables at baseline except 
for pain on squatting (  ﬁ  gure 3  ). For this variable, the BoNT-A 
group reported a mean pain score of 60.6/100, whereas the pla-
cebo group mean score was 40.3/100 (p<0.001).   Participants 
reported mean baseline AKPS scores of 65/100 (BoNT-A group) 
and 69/100 (placebo group), which implies moderate pain and 
disability.  17   All subjects reported having signiﬁ  cantly reduced 
their involvement in pain-provoking physical activity in order 
to control their symptoms.   
  Reported compliance with the home exercise programme 
was excellent for all subjects and 93% of all scheduled 
follow-up appointments to 6 months postinjection were 
attended. 
    Phase I (12-week comparison) 
  Data are presented in   ﬁ  gures 3   and   4  .     
    Improvement between baseline and 12 weeks was sig- 1. 
niﬁ  cantly greater for BoNT-A than placebo-injected sub-
jects for the AKPS (p<0.03) (  ﬁ  gure 3A  ), pain on kneeling 
  Figure  3         The mean (±SE) change between baseline and 12 weeks post-injection for self-reported knee-related disability (A) and activity-
induced pain (B) is depicted for botulinum toxin type A (BoNT-A)-injected and placebo groups. Statistically signiﬁ  cant differences * were seen 
between groups for four of ﬁ  ve parameters measured, favouring the BoNT-A-injected group. AKPS, anterior knee pain scale.       
  Figure  4         (A) A signiﬁ  cant change in vastus medialis (VM) activation 
in the botulinum toxin type A (BoNT-A)-injected group only (*), during 
static quadriceps contraction at 30° knee ﬂ  exion, occurred by week 2 
(W2), which was sustained at week 12 (#). The dotted line represents 
parity of vastus lateralis (VL):VM activation. (B) There was no change 
in the mean (±SE) peak knee extensor force between BoNT-A-injected 
and placebo groups, or for the effect of time. B, baseline; W, week.       
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(p<0.004), squatting (p<0.02) and level walking (p<0.04) 
(  ﬁ  gure 3B  ).   
    Change in AKPS scores exceeded the minimal clinically  2. 
important difference  14   in the BoNT-A-injected subjects 
only (mean increase 15 points, p<0.001) (  ﬁ  gure 3A    ).     
    The BoNT-A-injected group demonstrated a clinically sig- 3. 
niﬁ  cant change  16   in mean pain scores for kneeling (−50.5, 
p<0.001), stair walking (−20.9, p<0.006), squatting (−30.8, 
p<0.001) and level walking (−20.3, p<0.003). In placebo sub-
jects, there was a reduction for stair walking only (−20.4); 
however, this was not a statistically signiﬁ  cant  change 
from baseline (p<0.097) (  ﬁ  gure 3B  ).   
    A dominant pattern of VL activation was present at base- 4. 
line in all subjects  11     12   (  ﬁ  gure 4A  ). The normalised ratio of 
VM:VL amplitude during isometric quadriceps contraction 
was reversed at week 2, and remained signiﬁ  cantly different 
to baseline in the BoNT-A-injected group at all timepoints 
postinjection (  ﬁ  gure 4A  ) (p<0.001). Ratios in the placebo-
injected subjects also became closer to 1:1 but the differ-
ence from baseline was not signiﬁ  cant at any time point 
postinjection (  ﬁ  gure 4A  ).   
    There was a small improvement in peak knee extensor  5. 
force over time in the placebo group but not in the BoNT-
A-injected group (  ﬁ  gure 4B  ). The difference between groups 
was not signiﬁ  cant at any time point.       
    Phase II (crossover and long-term follow-up) 
  At 12 weeks postinjection, ﬁ  ve subjects elected to receive an 
open-label injection of Dysport on the basis that their symp-
toms  w e re  unchanged.  Self-repo rted  pain  and  knee-rela ted  
disability for these crossover subjects showed improvement 
beyond the second baseline (  ﬁ  gure 5  ). Statistical analysis was 
not performed due to the small number of subjects in the 
crossover group. When group allocation was unmasked at 
24 weeks, all ﬁ  ve crossover subjects were found to have ini-
tially received placebo injection. An additional four subjects 
did not consider that they had made any improvement at 
12 weeks but elected not to crossover due to travel or study 
commitments. Two of these individuals had received Dysport 
injection in phase I.   
  At 24 weeks after the initial injection all subjects com-
pleted an exit questionnaire. Twenty of 24 subjects correctly 
  identiﬁ  ed their group allocation. Two placebo-injected sub-
jects thought that they had received the active drug injection 
and two BoNT-A-injected subjects were unsure if they had 
received the active treatment. 
  At 24 weeks, 16 out of 19 BoNT-A-treated subjects reported 
that they were highly satisﬁ  ed (8/19) or satisﬁ  ed (8/19), whereas 
three of 19 were dissatisﬁ  ed with treatment outcomes. The 
reasons for dissatisfaction included ongoing activity-induced 
pain (two subjects) and a perception of asymmetry of the dis-
tal aspect of the quadriceps muscle (one subject). One of the 
  placebo-only subjects was highly satisﬁ  ed, one was satisﬁ  ed 
and the remaining placebo-injected subjects were dissatisﬁ  ed 
with treatment outcomes due to persistent or worsening pain. 
  Long-term data for pain (VAS) and knee-related disability 
(AKPS) were available for 17 of the 24 subjects enrolled in the 
study (with a mean follow-up of 20±8 months from injec-
tion). Sustained improvement was reported in 11 of 14 BoNT-
A-injected subjects. One BoNT-A-injected subject elected 
to have knee surgery at 14 months postenrolment, and two 
had regressed to close to baseline by 12 months. Two of the 
ﬁ  ve placebo-only subjects had maintained the improvements 
observed at 6 months, one had regressed to worse than base-
line and two were lost to follow-up.   
  Figure  5         Data for the crossover subgroup (n=5) for self-reported knee-related disability (anterior knee pain scale; AKPS) and activity induced 
pain (visual analogue scale) for four pain-provoking tasks taken during the initial 12-week placebo phase. The subsequent post-botulinum toxin 
type A (BoNT-A) injection phase resulted in a further improvement from the second baseline (B2).       
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  Adverse  effects 
  Few adverse effects were reported, and all related to slight 
bruising or injection-related pain, which resolved within days. 
Slight distal thigh asymmetry, which persisted to at least 
24 weeks postinjection, was present in six BoNT-A-injected 
subjects. Only one subject perceived this to be an adverse 
outcome.     
  DISCUSSION 
  The aim of this randomised controlled trial was to examine 
the effect of the intramuscular injection of BoNT-A (Dysport) 
to the distal portion of the VL muscle, in addition to a stan-
dar d  h o m e  e x e r cis e  p r o gr amm e ,  to  r e m e di a te  l o ng s tan ding  
AKP in carefully selected subjects with demonstrated VL mus-
cle dominance. The group studied had an average duration of 
knee symptoms of 5.7 years (range 1–10); and had exhausted 
conservative management, including having previously per-
formed similar exercises to those that were undertaken as part 
of the study. Data presented support the hypothesis that this 
novel intervention has the potential to induce improvements 
in longstanding knee pain and disability. Importantly, these 
improvements outlasted the 12 weeks expected duration of 
the drug effect based on animal studies.  10   
  The mechanisms underlying these improvements may be 
partly elucidated from the present study. The ratio of VM to 
VL muscle activation during isometric knee extension was 
reversed following BoNT-A injection. That is, as early as 
2 weeks postinjection, the VM showed the greatest activa-
tion during isometric knee extension; whereas previously 
the VL was dominant. In the placebo group, the ratio of VM 
to VL muscle activation also changed, although to a much 
lesser extent, suggesting that the injection itself had some 
inﬂ  uence on muscle activation, which persisted for at least 
12 weeks (  ﬁ  gure 4A  ). However, in contrast to the BoNT-A-
injected subjects, the VM:VL ratio in placebo subjects was 
not signiﬁ  cantly different from baseline at any time point 
(  ﬁ  gure 4A  ). There was a steady improvement in knee exten-
sor force production over the 12-week period in placebo 
subjects (    ﬁ  gure 4B  ). Peak force, which might be expected 
to have reduced in BoNT-A-injected subjects as a result of 
relative weakening of the distal VL muscle, was maintained 
(    ﬁ  gure 4B  ). Some subjects noted an ability to recruit and sus-
tain a contraction of the VM muscle within a week of the 
injection; something that they had been unable to achieve 
previously, despite, in some cases, electrical muscle stimula-
tion and EMG biofeedback training. It is acknowledged that 
this may have led them to conclude that they had received 
the active treatment, with the potential for bias of subse-
quent self-reports; however, it is difﬁ  cult to accept that this 
would have inﬂ  uenced quadriceps muscle activation ratios, 
which are not under volitional control.  18  
    Limitations of the study 
  The relatively small numbers recruited for this study, as well 
as the speciﬁ   c inclusion and exclusion criteria used, mean 
that the sample is not broadly representative of all individu-
als with chronic AKP. The groups were well matched apart 
from gender allocation. The greater incidence of AKP in 
women is well described  19     20  ; however, it is possible that the 
gender inequity between groups may have confounded the 
results, particularly with respect to gender-based differences 
in strength and motor control.  21   Future studies are needed to 
explore this issue. 
  It is well accepted that quadriceps muscle imbalance is only 
one of many factors contributing to AKP.  2     3   Indeed, only 26 of 
the 51 cases assessed, all of whom presented with symptoms 
suggestive of AKP,  1   were found to have VL dominance on sur-
face EMG evaluation. However, the present cohort represents 
a group who are frequently considered for surgery. Cases with 
refractory AKP associated with maltracking may undergo sur-
gical procedures such as lateral retinacular release and tibial 
tubercle alignment. The evidence that patella malalignment 
is the primary cause of AKP is limited and is based on mea-
sures with poor reliability and/or validity.  22   Given the lack of 
evidence for a clear relationship between patellofemoral joint 
alignment and symptoms, it could be speculated that surgical 
correction may not be the optimal approach to alleviate symp-
toms of AKP. Botulinum toxin injection is a safe, reversible treat-
ment that does not interfere with patellofemoral joint integrity  .   
In combination with careful assessment and management of 
contributing factors, BoNT-A injection has the potential to be 
a cost-effective treatment for carefully selected AKP patients, 
who are refractory to conservative management. In some cases, 
BoNT-A injection may alleviate the need for surgery. Further 
investigation of the utility of BoNT-A in larger cohorts with 
refractory AKP, including patients wait-listed for surgery, and 
with a longer follow-up, would appear to be merited. 
  From our investigation, it could be speculated that the injec-
tion of BoNT -A into the distal VL muscle improved neuro-
motor control of the quadriceps, which facilitated normal 
patellofemoral mechanics. Draper   et al    23   have reported the 
utility of open magnetic resonance imaging and a semi-erect 
dynamic knee ﬂ   exion protocol to demonstrate abnormal 
patellofemoral joint kinematics in individuals with AKP. In 
future studies it would be valuable to examine changes in 
physiologically loaded patellofemoral joint kinematics as an 
outcome of BoNT -A treatment of AKP , in addition to self-
  reported pain and disability.     
  C O N C L U S I O N  
  This study extends our previous open-label study   examining 
the efﬁ  cacy of a focal injection of BoNT-A for individuals with 
refractory AKP associated with quadriceps muscle imbalance.  9   
The improvement between baseline and 12 weeks was signiﬁ  -
cantly greater for BoNT-A than placebo-injected subjects for the 
AKPS, pain on kneeling, squatting and level walking. BoNT-A 
injection was associated with improved activation of VM mus-
cle without compromise to isometric knee extensor force pro-
duction. Individuals who received Dysport either as an initial 
or crossover treatment were generally satisﬁ  ed or highly satis-
ﬁ  ed with outcomes at 6 months postinjection. Improvements 
were maintained in the majority of BoNT-A-injected subjects 
available for follow-up to a mean of 20 months.                            
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What is already known on this topic
  AKP is prevalent in active individuals, more frequently noted    ▶
in women.
  Patella maltracking secondary to disturbed quadriceps func-   ▶
tion is commonly assumed to contribute to this problem.
  As a result of a constellation of diagnoses for AKP, a diverse    ▶
range of conservative and surgical treatment alternatives 
exist, many without sound evidence for efﬁ  cacy.
What this study adds
  A single injection of BoNT-A, plus a conventional exercise    ▶
programme, may provide a conservative treatment option 
to restore quadriceps muscle balance in individuals with 
refractory AKP.
  This study provides support for a novel application of    ▶
BoNT-A to improve neuromotor control of the knee extensor 
mechanism and alleviate chronic AKP.
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